Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
作者： F Nathan , C Khater , N Haas , M Cornfield , B Giantonio
DOI: 10.1200/JCO.1997.15.9.3156
关键词:
摘要: PURPOSETo evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC).PATIENTS AND METHODSThirty-four adenocarcinoma that progressed after one or more hormonal therapies a trial antiandrogen withdrawal were enrolled onto this phase II trial. Patients received 120 mg/m2 by intravenous (i.v.) infusion on days 1 through 4 each 21-day cycle, together EMP 600 mg/m2/d, continuously.RESULTSFour nine measurable disease had objective responses (one complete response [CR] three partial [PRs]) liver (two patients) nodes 2, 6, 8, 20 months' duration. Of 25 assessable metastases limited to bone, 14 > = 50% decline pretreatment prostate-specific antigen (PSA) level sustained for at least 6 weeks seven 80% decline. Overall, 17 32 patient...
sci-hub.se 参考文章(29)
Björn Dahllöf, Fernando Cabral, Anita Billström, Beryl Hartley-Asp, Estramustine depolymerizes microtubules by binding to tubulin Cancer Research. ,vol. 53, pp. 4573- 4581 ,(1993)
Gary R. Hudes, Kenneth D. Tew, Sulabha Ranganathan, Andrew E. Chapman, Dwayne W. Dexter, Christopher A. Benetatos, Increase of βIII- and βIVa-Tubulin Isotypes in Human Prostate Carcinoma Cells as a Result of Estramustine Resistance Cancer Research. ,vol. 56, pp. 2584- 2589 ,(1996)
M A Eisenberger, R Simon, P J O'Dwyer, R E Wittes, M A Friedman, A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. Journal of Clinical Oncology. ,vol. 3, pp. 827- 841 ,(1985) , 10.1200/JCO.1985.3.6.827
A Sella, R Kilbourn, R Amato, C Bui, A A Zukiwski, J Ellerhorst, C J Logothetis, Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Journal of Clinical Oncology. ,vol. 12, pp. 683- 688 ,(1994) , 10.1200/JCO.1994.12.4.683
Bruce J. Roth, Patrick J. Loehrer, Beow Yong Yeap, George Wilding, Basil Kasimis, David McLeod, Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group Cancer. ,vol. 72, pp. 2457- 2460 ,(1993) , 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z
Roy G. Burns, Stoichiometry of estramustine phosphate binding to MAP2 measured by the disassembly of chick brain MAP2: Tubulin microtubules Cell Motility and the Cytoskeleton. ,vol. 17, pp. 167- 173 ,(1990) , 10.1002/CM.970170304
Naomi Laing, Bjorn Dahllöf, Beryl Hartley-Asp, Sulabha Ranganathan, Kenneth D. Tew, Interaction of Estramustine with Tubulin Isotypes Biochemistry. ,vol. 36, pp. 871- 878 ,(1997) , 10.1021/BI961445W
Kenneth D. Tew, Jenny P. Glusker, Beryl Hartley-Asp, Gary Hudes, Lisa A. Speicher, Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacology & Therapeutics. ,vol. 56, pp. 323- 339 ,(1992) , 10.1016/0163-7258(92)90023-S
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Charles D. Smith, Jack T. Zilfou, Xinqun Zhang, Gary R. Hudes, Kenneth D. Tew, Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins Cancer. ,vol. 75, pp. 2597- 2604 ,(1995) , 10.1002/1097-0142(19950515)75:10<2597::AID-CNCR2820751030>3.0.CO;2-R